<DOC>
	<DOCNO>NCT02437110</DOCNO>
	<brief_summary>Background : - Some people Amyotrophic Lateral Sclerosis ( ALS ) high level virus HERV-K blood . Researchers think virus cause ALS . But know people ALS high level . They want know HERV-K suppress drug use treat HIV infection . Objectives : - To learn drug usually take HIV infection affect people Amyotrophic Lateral Sclerosis ( ALS ) . Eligibility : - Adults least 18 year old ALS high level HERV-K HIV . Design : - Participants screen medical history , physical exam , blood breathing test . - Visit 2 : participant medical history , questionnaire , blood drawn . Their strength test push machine . They blow tube measure air hold lung . - After Visit 2 , participant start take 4 study drug twice day . - Participants study visit Weeks 1 , 2 , 4 , every 4 week Week 36 . They ask feel exam blood drawn . At 2 visit , test strength , breathing , ALS symptom . Some visit may do ALS doctor office . - At Week 24 , stop taking study drug . - After Week 36 visit , participation finish .</brief_summary>
	<brief_title>HERV-K Suppression Using Antiretroviral Therapy Volunteers With Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description>Objective : In Phase I , proof-of-concept study , aim determine whether antiretroviral regimen approve treat human immunodeficiency virus ( HIV ) infection would also suppress level Human Endogenous Retrovirus-K ( HERV-K ) find activated subset patient amyotrophic lateral sclerosis ( ALS ) . We propose measure level plasma expression gag , env , pol RNA transcripts HERV-K quantitative PCR , , treatment antiretroviral regimen . We evaluate safety antiretroviral regimen participant ALS also explore clinical outcome ALS symptom , quality life , motor strength , pulmonary function . Study Population We study subset ALS patient plasma level HERV-K gag transcript &gt; 1000 copies/ml . About 30 % ALS patient may detectable level HERV-K ; 10 % patient ALS level &gt; 1000 copies/ml . To show whether HERV-K could suppress , recruit approximately 10 % patient high level antiretroviral effect determine . Design This open-label study combination antiretroviral therapy 24 week 10 HIV-negative , HTLV-negative ALS patient high plasma level HERV-K gag . The study duration participant approximately 44 week 8-week screening window , 24-week treatment phase , 12-week follow-up phase . If participant undetectable ( &lt; 100 copies/ml ) level HERV-K gag RNA two consecutive study visit end 24-week treatment phase , study drug discontinue primary outcome satisfy point . Participants stay antiretroviral regimen least 8 week regardless undetectable HERV-K gag RNA level prior . Participants follow regularly safety clinical outcome . Outcome Measures The primary outcome proportion participant ALS undetectable ( &lt; 100 copies/ml ) plasma level HERV-K gag RNA expression measure quantitative PCR within 24 week start antiretroviral regimen darunavir + ritonavir , raltegravir , zidovudine . The secondary objective : ( ) proportion participant ALS undetectable ( &lt; 100 copies/ml ) plasma level either HERV-K pol env RNA transcript within 24 week start antiretroviral regimen ; ( b ) safety antiretrovirals volunteer ALS measure frequency type adverse event ( AEs ) , ability remain assigned treatment ( tolerability ) , physical examination , laboratory test result , vital sign , weight/body mass index ( BMI ) . Efficacy explore measure change mean score : ALS Functional Rating Scale-Revised ( ALSFRS-R ) , ALS Specific Quality Life Inventory-Revised ( ALSSQOL-R ) , vital capacity measure handheld spirometer , quantitative muscle test dynamometry .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Darunavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects must meet follow inclusion criterion eligible participate study : Age 18 year old time screen visit . Able provide inform consent comply study procedure . ALS diagnose probable , laboratorysupported probable definite accord World Federation Neurology El Escorial revise criteria31 determine neurologist neuromuscular subspecialty training . Detectable plasma HERVK gag RNA transcript minimum 1000 copies/ml measure quantitative PCR screen visit . Vital capacity least 60 % predict value gender , height age screen visit If take riluzole , must stable dose least 30 day prior screen visit , stop take riluzole least 30 day prior screen visit . Subject competent caregiver responsible administer study drug . If caregiver , another qualified individual must available . Subject establish care neurologist specialize ALS clinic maintain clinical care throughout study . EXCLUSION CRITERIA : A participant exclude following : Dependence daytime mechanical ventilation ( invasive noninvasive , include Continuous Positive Airway Pressure ( CPAP ) Bilevel Positive Airway Pressure ( BiPap ) time screen visit . History undergone gastrostomy time screen . Participation investigational drug trial use investigational drug ( within 12 week prior Screening thereafter ) . Known sulfonamide allergy . History positive test positive result screen HIV HTLV1 . Women must able become pregnant ( e.g. , post menopausal least one year , surgically sterile , use adequate method contraception ) breastfeed duration study . Adequate method contraception include : implanted contraception , intrauterine device place least 3 month , barrier method conjunction spermicide . Women childbearing potential must negative pregnancy test screen nonlactating . Presence follow clinical condition time screening : Drug abuse alcoholism Unstable medical disease ( unstable angina chronic obstructive pulmonary disease ) , active infectious disease ( Hepatitis C tuberculosis ) , current malignancy Unstable psychiatric illness define psychosis untreated major depression within 90 day screen visit Dementia Diabetes mellitus Hemophilia Use contraindicate medication : amiodarone , dronederone , lovastatin , simvastatin , rifampin , rifapentine , cisapride , pimozide , midazolam , triazolam , dihydroergotamine , ergonovine , ergotamine , methylergonovine , St. John wort , alfuzosin , salmeterol , sildenafil pulmonary arterial hypertension . Safety Laboratory Criteria screen visit : Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) great 3.0 time upper limit normal NIH Clinical Center . Total bilirubin , lactateL , triglyceride , amylase , lipase great 2.0 time upper limit normal NIH Clinical Center . Creatine kinase great 3.0 time upper limit normal NIH Clinical Center . Absolute neutrophil count &lt; 1000/ ( micro ) l. Platelet concentration &lt; 100,000/ ( micro ) l. Hemoglobin &lt; 10mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 1, 2017</verification_date>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
	<keyword>Virus</keyword>
	<keyword>Antiretroviral Therapy</keyword>
</DOC>